SCHEMBL22010746

SCHEMBL22010746

C=CCCc1c(CC)nc(OC[C@H]2C[C@@H](F)CC2C)nc1N1CCN[C@@H](CC#N)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22011304 0.66 KRAS (0.34) —
SCHEMBL25021516 0.65 KRAS (0.39) —
SCHEMBL25021052 0.65 KRAS (0.39) —
SCHEMBL25019964 0.65 PRKCQ (0.30) —
SCHEMBL25019891 0.64 KRAS (0.39) —
SCHEMBL21846390 0.64 KRAS (0.46) —
SCHEMBL19637232 0.61 NUDT1 (0.33) —
SCHEMBL25019783 0.61 PRKCQ (0.30) —
SCHEMBL19637277 0.59 KRAS (0.35) —
SCHEMBL23156819 0.58 KRAS (0.45) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020101736-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-05-22 — — WO disclosed
Send feedback